🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. PH-10 (0.001% Rose Bengal)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Psoriasis

    phase 2 small molecule completed

    1 trial

  2. PH-10 (0.002% Rose Bengal)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Psoriasis

    phase 2 small molecule completed

    1 trial

  3. PH-10 (rose bengal disodium 0.001%)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Plaque Psoriasis

    phase 2 small molecule terminated

    1 trial

  4. PHE885

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  5. PI-88

    Biotech Pharmaceutical Co.,

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  6. PKN605, Placebo to PKN605 50 mg film-coated tablets

    Novartis Pharmaceuticals

    Atrial Fibrillation

    phase 2 small molecule active

    1 trial

  7. PLACEBO, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, -

    Lacuna Pharma Pty Ltd

    allergic rhinoconjunctivitis caused due to exposure to pollen grasses

    phase 2 small molecule active

    1 trial

  8. PLACEBO, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, -

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis caused due to exposure to pollen grasses

    phase 2 small molecule active

    1 trial

  9. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 2 small molecule active

    1 trial

  10. PPY988A

    Novartis Pharmaceuticals

    Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).

    phase 2 small molecule active

    1 trial

  11. PREGABALIN, VX-993 tablet, VX-993 Placebo, VX-993 tablet, PREGABALIN, Pregabalin placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  12. PRO044 SC

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  13. PRO044 SC 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  14. PRO045, 0.15 mg/kg/week

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  15. PROMETHAZINE , DIPHENHYDRAMINE , CETIRIZINE , DEXCHLORPHENIRAMINE , PARACETAMOL , SAR443579

    Sanofi-aventis Healthcare Pty Ltd

    Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia

    phase 2 small molecule active

    1 trial

  16. PS433540

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

  17. PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  18. PV-10

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Melanoma

    phase 2 small molecule active

    2 trials

  19. PV-10 (10% rose bengal disodium)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Melanoma

    phase 2 small molecule completed

    1 trial

  20. Paclitaxel

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  21. Paclitaxel

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. Panobinostat

    Novartis Pharmaceuticals

    Classical Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  23. Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

    CASI Pharmaceuticals

    Carcinoid Tumor

    phase 2 small molecule completed

    1 trial

  24. Panzem NCD

    CASI Pharmaceuticals

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources